A Phase I/II Randomised Therapeutic HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection
Latest Information Update: 08 Apr 2022
Price :
$35 *
At a glance
- Drugs HIV DNA vaccine (Primary) ; MVA HIV vaccine (Primary) ; Vedolizumab
- Indications HIV-1 infections
- Focus Adverse reactions; First in man; Therapeutic Use
- 03 Apr 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 21 Jul 2019 Status changed from recruiting to discontinued.
- 23 Mar 2019 This trail is suspended in spain.